| Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome NJ Samadder, D Riegert-Johnson, L Boardman, D Rhodes, M Wick, ... JAMA oncology 7 (2), 230-237, 2021 | 202 | 2021 |
| Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis MB Sonbol, IB Riaz, SAA Naqvi, DR Almquist, S Mina, J Almasri, S Shah, ... JAMA oncology, e204930-e204930, 2020 | 157 | 2020 |
| Germline cancer susceptibility gene testing in unselected patients with colorectal adenocarcinoma: a multicenter prospective study PLS Uson Jr, D Riegert-Johnson, L Boardman, J Kisiel, L Mountjoy, ... Clinical Gastroenterology and Hepatology 20 (3), e508-e528, 2022 | 56 | 2022 |
| The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer JE Berchuck, F Facchinetti, DF DiToro, I Baiev, U Majeed, S Reyes, ... Annals of Oncology 33 (12), 1269-1283, 2022 | 50 | 2022 |
| Continuous palliative sedation for patients with advanced cancer at a tertiary care cancer center BL Prado, DBD Gomes, PLS Usón Júnior, P Taranto, MS França, D Eiger, ... BMC Palliative Care 17, 1-7, 2018 | 49 | 2018 |
| Immune checkpoint inhibitors as therapy to down-stage hepatocellular carcinoma prior to liver transplantation NN Katariya, BC Lizaola-Mayo, DM Chascsa, E Giorgakis, BA Aqel, ... Cancers 14 (9), 2056, 2022 | 28 | 2022 |
| A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma DH Ahn, PLS Uson Junior, P Masci, H Kosiorek, TR Halfdanarson, ... Investigational new drugs 40 (1), 134-141, 2022 | 28 | 2022 |
| Clinical impact of pathogenic germline variants in pancreatic cancer: results from a multicenter, prospective, universal genetic testing study PLS Uson Jr, NJ Samadder, D Riegert-Johnson, L Boardman, MJ Borad, ... Clinical and translational gastroenterology 12 (10), e00414, 2021 | 26 | 2021 |
| Assessment of adherence to the guidelines for the management of nausea and vomiting induced by chemotherapy MS França, PLS Usón, YPPV Antunes, BL Prado, CC Donnarumma, ... Einstein (Sao Paulo) 13 (2), 221-225, 2015 | 25* | 2015 |
| Circulating tumor DNA (ctDNA) based testing and actionable findings in patients with advanced and metastatic pancreatic adenocarcinoma G Botrus, H Kosirorek, MB Sonbol, Y Kusne, PLSU Junior, MJ Borad, ... The oncologist, 2021 | 24 | 2021 |
| Meta-analysis of modified FOLFIRINOX regimens for patients with metastatic pancreatic cancer PLSU Junior, ET Rother, FC Maluf, DDG Bugano Clinical Colorectal Cancer 17 (3), 187-197, 2018 | 23 | 2018 |
| Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer MFC Usón Junior PLS, Callegaro-Filho D, Bugano DDG, Moura F Journal of Gastrointestinal Cancer 49 (4), 481-486, 2017 | 23* | 2017 |
| The impact of metastatic sites in advanced pancreatic adenocarcinoma, systematic review and meta-analysis of prospective randomized studies PLS Usón, FDAS Tolentino, VM Santos, ET Rother, FC Maluf PloS One 15 (3), e0230060, 2020 | 20 | 2020 |
| Incidental findings in reduction mammoplasty specimens in patients with no prior history of breast cancer. An analysis of 783 specimens PLS Usón Junior, D Callegaro Filho, DDG Bugano, FC Geyer, ... Pathology & Oncology Research 24, 95-99, 2018 | 18 | 2018 |
| Higher overall survival in metastatic pancreatic cancer: the impact of where and how treatment is delivered PLS Usón Junior, MS França, HV Rodrigues, ALV Macedo, A Goldenberg, ... Einstein (Sao Paulo) 13, 347-351, 2015 | 18* | 2015 |
| Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer Cancer Chemotherapy and Pharmacology 8, 10, 2020 | 17* | 2020 |
| Does time-to-chemotherapy impact the outcomes of resected ovarian cancer? Meta-analysis of randomized and observational data PLS Usón, DDG Bugano, MS França, YPPV Antunes, P Taranto, ... International Journal of Gynecologic Cancer 27 (2), 2017 | 17 | 2017 |
| Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond PLS Uson Junior, MJ Borad Expert Opinion on Investigational Drugs 31 (1), 125-131, 2022 | 16 | 2022 |
| Signet ring cell component, not the Lauren subtype, predicts poor survival: an analysis of 198 cases of gastric cancer PLSUJ Vladimir Galvão de Aguiar, Vanderlei Segatelli, Antônio Luís de ... Future Oncology, 2019 | 14 | 2019 |
| Precision medicine targeting FGFR2 genomic alterations in advanced cholangiocarcinoma: current state and future perspectives M Zugman, G Botrus, RC Pestana, PLS Uson Junior Frontiers in Oncology 12, 860453, 2022 | 13 | 2022 |
Mitesh J. BoradMayo ClinicVerified email at mayo.edu
